Article Text

Download PDFPDF

O-3 Opioids, benzodiazepines, anti-cholinergic load and clinical outcomes in patients with advanced cancer
  1. Jason W Boland1,
  2. Victoria Allgar2,
  3. Elaine G Boland1,3,
  4. Osaretin Oviasu1,
  5. Meera Agar4,5,6,
  6. David C Currow1,4,5 and
  7. Miriam J Johnson1
  1. 1Hull York Medical School, University of Hull, Hull, UK
  2. 2University of York, York, UK
  3. 3Hull and East Yorkshire Hospitals NHS Trust, Hull, UK
  4. 4University of Technology Sydney, Sydney, Australia
  5. 5Discipline, Palliative and Supportive Services, Flinders University, Adelaide, South Australia
  6. 6Ingham Institute of Applied Medical Research, Sydney, Australia


Background Medications used to manage symptoms in patients with cancer have associated, but poorly understood, harms. The aim of this study was to explore the temporal relationship between oral morphine equivalent daily dose (MEDD), oral diazepam equivalent daily dose (DEDD) and the daily anti-cholinergic load (ACL) with cognitive and gastrointestinal symptoms, performance status, quality of life and survival in patients receiving palliative care.

Methods Secondary longitudinal analysis of cancer decedents (n=235) from a palliative care trial with multiple outcome measures. At each time-point MEDD, DEDD and ACL were calculated. Multilevel modelling was used to investigate ?independent associations between MEDD, DEDD and ACL, and cognitive and gastrointestinal symptoms, quality of life, performance status and survival.

Results Cognitive and gastrointestinal symptoms, performance status, and quality of life worsened over time. In the adjusted multilevel analysis significance remained for worsening performance status (MEDD, p=0.001; DEDD, p<0.001; ACL p=0.035) and shorter time to death (MEDD, p<0.001; ACL, p<0.01).

Conclusion Commonly used palliative medications were associated with deteriorating performance status and shorter time to death. This analysis highlights the importance of adjusting for other variables, including other medication when exploring medication-related harms. An understanding of the risk-benefit balance of medications is needed to maximise net benefit for patients. Future work to delineate interactions between classes of drugs and drug-related harms and to evaluate early assessment and management of side-effects is needed in order to maximise net benefit.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.